Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis.
No Thumbnail Available
All Authors
Manning, JE.
Ciantar, E.
Griffin, M.
Kelly, RJ.
LTHT Author
Ciantar, Etienne
Griffin, Morag
Kelly, Richard
Griffin, Morag
Kelly, Richard
LTHT Department
Obstetrics & Gynaecology
Oncology
Haematology
Oncology
Haematology
Non Medic
Publication Date
2025
Item Type
Systematic Review
Journal Article
Meta-Analysis
Journal Article
Meta-Analysis
Language
Subject
Subject Headings
Abstract
The co-occurrence of Paroxysmal nocturnal haemoglobinuria (PNH) and pregnancy has traditionally been associated with poor feto-maternal outcomes. Eculizumab, a terminal complement inhibitor, is often used in pregnant patients, but the drug is not universally available. We therefore present the first systematic review with meta-analysis of outcomes in 190 pregnancies from 135 PNH patients, comparing those receiving eculizumab and those not. We searched PubMed for studies reporting on pregnancy outcomes in PNH. Thirty-five papers were selected for inclusion, the majority of which were case studies or small series. Eculizumab was used in 131 pregnancies. There was one maternal death reported in a woman who did not receive eculizumab. A higher rate of fetal survival was observed in pregnancies where eculizumab was used (82%) than those when it was not (69%). Miscarriage (< 24 weeks gestation) occurred twice as often in women not receiving eculizumab. Intrauterine death (>=24 weeks gestation), maternal thrombosis, bleeding (both antepartum and postpartum), and pre-eclampsia were over-represented in PNH pregnancies but did not significantly differ between treatment groups. Premature birth (< 37 weeks' gestation) was observed in 32% of eculizumab pregnancies and 44% of non-eculizumab pregnancies. We conclude that Eculizumab appears to be safe and benefits pregnant women with PNH.
Journal
Annals of Hematology